Compass Therapeutics (NASDAQ:CMPX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Compass Therapeutics (NASDAQ:CMPX) issued its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports.

Compass Therapeutics Stock Up 3.4 %

NASDAQ CMPX traded up $0.10 during trading hours on Thursday, reaching $3.07. 339,566 shares of the company were exchanged, compared to its average volume of 1,977,039. The stock has a market capitalization of $422.40 million, a P/E ratio of -8.31 and a beta of 1.17. The business’s 50 day simple moving average is $2.52 and its 200-day simple moving average is $1.92. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.08.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CMPX shares. D. Boral Capital reissued a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective for the company. Guggenheim assumed coverage on Compass Therapeutics in a research note on Monday. They set a “buy” rating and a $12.00 target price for the company. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.